Dr. Anna Arbuzova

Dr. Arbuzova erforscht die supramolekulare Selbstorganisation von cholesterolmodifizierten Nukleosiden und lipophilen Nukleinsäuren in Membransystemen. Ihr aktueller Fokus liegt auf der kontrollierten Bildung von Nano- und Mikroröhren aus amphiphilen Molekülen sowie auf der gezielten Funktionalisierung von Lipidmembranen durch DNA-Hybridisierung und enzymatische Steuerung. Diese Arbeiten ermöglichen neue Ansätze für Wirkstoffabgabesysteme (Drug Delivery), Biosensoren und die programmierbare Strukturierung von Oberflächen — relevant für Pharmazie, Diagnostik und Nanotechnologie. Die Kombination aus chemischer Synthese, Membranbiophysik und molekularer Steuerung bietet Industriepartnern eine Plattform für die Entwicklung intelligenter, triggerbar freisetzbarer Liposomen und membrangebundener Funktionselemente.

🔒 Das System hat 200 mögliche Industrie-Partner gefunden — Firmen, Scores und Begründungen sind nur für eingeloggte Nutzer:innen sichtbar. Anmelden

• Supramolekulare Organisation von Cholesterol-modifizierten Nukleosiden in Mikroröhren: Charakterisierung und Funktionalisierung

  Quelle ↗

  Förderer: DFG Eigene Stelle (Sachbeihilfe) Zeitraum: 06/2011 - 09/2015 Projektleitung: Dr. Anna Arbuzova, Prof. Dr. rer. nat. Andreas Herrmann

• Lipid‐Anchored Oligonucleotides for Stable Double‐Helix Formation in Distinct Membrane Domains

  2006

  Angewandte Chemie International Edition · DOI

  Anchoring for DNA: A lipophilic oligonucleotide consisting of 21 thymidine units and two lipophilic nucleotides L was synthesized and bound to vesicular surfaces (see fluorescence image). The membrane-bound oligonucleotide binds complementary DNA strands by formation of Watson–Crick base pairs. The lipid-anchored oligonucleotide is preferentially enriched in liquid-disordered membrane domains.

• Reduction-Sensitive Liposomes from a Multifunctional Lipid Conjugate and Natural Phospholipids: Reduction and Release Kinetics and Cellular Uptake

  2011

  Langmuir · DOI

  The development of targeted and triggerable delivery systems is of high relevance for anticancer therapies. We report here on reduction-sensitive liposomes composed of a novel multifunctional lipidlike conjugate, containing a disulfide bond and a biotin moiety, and natural phospholipids. The incorporation of the disulfide conjugate into vesicles and the kinetics of their reduction were studied using dansyl-labeled conjugate 1 in using the dansyl fluorescence environmental sensitivity and the Förster resonance energy transfer from dansyl to rhodamine-labeled phospholipids. Cleavage of the disulfide bridge (e.g., by tris(2-carboxyethyl)phosphine (TCEP), dithiothreitol (DTT), l-cysteine, or glutathione (GSH)) removed the hydrophilic headgroup of the conjugate and thus changed the membrane organization leading to the release of entrapped molecules. Upon nonspecific uptake of vesicles by macrophages, calcein release from reduction-sensitive liposomes consisting of the disulfide conjugate and phospholipids was more efficient than from reduction-insensitive liposomes composed only of phospholipids. The binding of streptavidin to the conjugates did not interfere with either the subsequent reduction of the disulfide bond of the conjugate or the release of entrapped molecules. Breast cancer cell line BT-474, overexpressing the HER2 receptor, showed a high uptake of the reduction-sensitive doxorubicin-loaded liposomes functionalized with the biotin-tagged anti-HER2 antibody. The release of the entrapped cargo inside the cells was observed, implying the potential of using our system for active targeting and delivery.